ArticleMalaysian orthopaedic journal2026
Denosumab's Role in Reducing Type 2 Diabetes Risk and Improving Glycaemic Control in Osteoporotic Patients - A Meta-analysis.
Article in Malaysian orthopaedic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoporosis, common among postmenopausal women and the elderly, is primarily associated with increased fracture risk. Emerging evidence suggests a potential link between bone metabolism and glucose regulation with implications for type 2 diabetes (T2D) risk. Denosumab, a monoclonal antibody effective in increasing bone density, might also reduce the risk of T2D. This meta-analysis evaluates the impact of denosumab on T2D risk and glycaemic markers, including fasting blood sugar (FBS), HbA1c, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Materials and methods: A comprehensive search of PubMed, Cochrane Library, and Embase identified randomised controlled trials and cohort studies comparing denosumab with placebo or other osteoporosis treatments. Study quality was assessed using the Cochrane risk-of-bias tool. The primary outcome was T2D incidence, with risk ratios and related metrics analysed for consistency. Results: Results revealed a 22% reduction in T2D incidence with denosumab (HR = 0.78, 95% CI 0.70, 0.87, p<0.00001, I Conclusion: Denosumab may confer metabolic benefits beyond bone health, particularly in reducing T2D risk and improving FBS. While this aligns with its role in modulating bone turnover and RANKL inhibition, inconsistent outcomes for HbA1c and HOMA IR underscore the need for further investigation into its glycaemic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.